Old Web
English
Sign In
Acemap
>
authorDetail
>
Brent McHenry
Brent McHenry
Bristol-Myers Squibb
Renal cell carcinoma
Ipilimumab
Nivolumab
Checkmate
Pathology
2
Papers
22
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
2020
Journal of Clinical Oncology
Robert J. Motzer
Toni K. Choueiri
David F. McDermott
Thomas Powles
Jin Yao
Ron Ammar
Simon Papillon-Cavanagh
Shruti Shally Saggi
Brent McHenry
Petra Ross-Macdonald
Megan Wind-Rotolo
Show All
Source
Cite
Save
Citations (18)
A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).
2020
Journal of Clinical Oncology
Axel Bex
Paul Russo
Yoshihiko Tomita
Viktor Grünwald
Luz Margarita Ramirez
Brent McHenry
Robert J. Motzer
Show All
Source
Cite
Save
Citations (4)
1